Drug intelligence / Profile preview

durvalumab + fulvestrant + olaparib

Development stage: Unknown
Lead developer: Unicancer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intramuscular

Overview

A combination therapy consisting of durvalumab (immune checkpoint inhibitor), fulvestrant (estrogen receptor antagonist), and olaparib (PARP inhibitor). This combination is being investigated for the treatment of ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations or alterations in genes involved in homologous recombination repair (HRR) or microsatellite instability (MSI) status.

Targets

CD274 (Programmed cell death protein 1 ligand 1)PARP2 (Poly (adp-ribose) polymerase 2)ER (Estrogen receptor)

Beyond the preview

Go deeper on durvalumab + fulvestrant + olaparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab + fulvestrant + olaparib.

Explore the full profile